Lung magnetic resonance imaging in systemic sclerosis: a new promising approach to evaluate pulmonary involvement and progression.
Luna GarganiCosimo BruniDaniele De MarchiChiara RomeiSerena GuiducciSilvia Bellando-RandoneGiovanni Donato AquaroAlessia PepeEmanuele NeriStefano ColagrandeFabio FalaschiAlberto Moggi-PignoneAlessandro PingitoreMarco Matucci-CerinicPublished in: Clinical rheumatology (2020)
Lung MRI can detect SSc-related ILD, with good correlations with other ILD markers. STIR values, independently of HRCT appearance, may predict worsening lung involvement. Lung MRI, although very preliminary, is a promising tool that in a near future could help selecting patients for an early treatment of SSc-related ILD and a more appropriate use of HRCT. Key points • Lung MRI has the potential to differentiate inflammation-predominant versus fibrosis-predominant lesions, but it is not currently used in routine clinical practice to assess SSc-related ILD. • Lung MRI STIR and T1 values are significantly different between patients with and without SSc-related ILD. STIR values, independently of HRCT appearance, are also able to predict worsening lung involvement over time. • These preliminary data suggest that, in a near future, MRI could support the choice for an early treatment of SSc-related ILD, as well as a more appropriate use of HRCT.
Keyphrases
- interstitial lung disease
- systemic sclerosis
- magnetic resonance imaging
- contrast enhanced
- clinical practice
- rheumatoid arthritis
- end stage renal disease
- computed tomography
- oxidative stress
- machine learning
- pulmonary hypertension
- risk assessment
- peritoneal dialysis
- current status
- climate change
- drug induced
- deep learning